LYEL vs PATH · rev $61.0K vs P/E 19, rev $1.61B
Lyell Immunopharma Inc (LYEL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LYEL revenue for 2024-12-31 was $61.0K. Net income was -$343.0M. Revenue was down 53.1% from 2023-12-31 to 2024-12-31. LYEL currently screens at market cap $143.5M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LYEL currently screens at market cap $143.5M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LYEL and PATH stock pages for the full models.
Not investment advice.